2018 Hypotension Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Hypotension Market
![](/report_cover/10529/2018-hypotension-drug-development-hypotension-market_en.gif)
Hypotension affects an estimated 80 million population in the US and is one of the leading contributors to mortality. When the systolic and diastolic pressures are below 90/60, the condition is considered as Hypotension or low blood pressure, resulting in inadequate supply to the body parts. Different types of hypotension include- chronic asymptomatic hypotension, Orthostatic Hypotension, Neurally Mediated Hypotension and Severe Hypotension
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Hypotension pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Hypotension pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Hypotension pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Hypotension pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Hypotension pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Hypotension pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 HYPOTENSION PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Hypotension Pipeline Snapshot
2.3 Hypotension Pipeline by Phase
2.4 Hypotension Pipeline by Company
2.5 Hypotension Pipeline by Mechanism of Action
3 HYPOTENSION- COMPANY WISE PIPELINE ANALYSIS
BrePco Biopharma Ltd
La Jolla Pharmaceutical Company
Orient Europharma Co., Ltd.
Theravance Biopharma Inc
TrioxBio Inc
4 HYPOTENSION R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN HYPOTENSION PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 HYPOTENSION PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Hypotension Pipeline Snapshot
2.3 Hypotension Pipeline by Phase
2.4 Hypotension Pipeline by Company
2.5 Hypotension Pipeline by Mechanism of Action
3 HYPOTENSION- COMPANY WISE PIPELINE ANALYSIS
BrePco Biopharma Ltd
La Jolla Pharmaceutical Company
Orient Europharma Co., Ltd.
Theravance Biopharma Inc
TrioxBio Inc
4 HYPOTENSION R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN HYPOTENSION PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Hypotension Pipeline by Phase, H2- 2018
Figure 2: Hypotension Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Hypotension Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Hypotension Pipeline by Phase, H2- 2018
Figure 2: Hypotension Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Hypotension Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Hypotension Pipeline by Phase, H2- 2018
Hypotension Pipeline by Companies, H2- 2018
Hypotension Pipeline by Mechanism of Action, H2- 2018
Table 1: BrePco Biopharma Ltd Hypotension Pipeline Drugs, H2- 2018
Table 2: La Jolla Pharmaceutical Company Hypotension Pipeline Drugs, H2- 2018
Table 3: Orient Europharma Co., Ltd. Hypotension Pipeline Drugs, H2- 2018
Table 4: Theravance Biopharma Inc Hypotension Pipeline Drugs, H2- 2018
Table 5: TrioxBio Inc Hypotension Pipeline Drugs, H2- 2018
Hypotension Pipeline by Phase, H2- 2018
Hypotension Pipeline by Companies, H2- 2018
Hypotension Pipeline by Mechanism of Action, H2- 2018
Table 1: BrePco Biopharma Ltd Hypotension Pipeline Drugs, H2- 2018
Table 2: La Jolla Pharmaceutical Company Hypotension Pipeline Drugs, H2- 2018
Table 3: Orient Europharma Co., Ltd. Hypotension Pipeline Drugs, H2- 2018
Table 4: Theravance Biopharma Inc Hypotension Pipeline Drugs, H2- 2018
Table 5: TrioxBio Inc Hypotension Pipeline Drugs, H2- 2018